U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H43NO5
Molecular Weight 449.6233
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of URSODEOXYCHOLYLGLYCINE

SMILES

C[C@H](CCC(=O)NCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

InChIKey=GHCZAUBVMUEKKP-XROMFQGDSA-N
InChI=1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1

HIDE SMILES / InChI

Molecular Formula C26H43NO5
Molecular Weight 449.6233
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
Patents
Substance Class Chemical
Created
by admin
on Tue Mar 06 16:01:05 UTC 2018
Edited
by admin
on Tue Mar 06 16:01:05 UTC 2018
Record UNII
PF1G5J2X2A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
URSODEOXYCHOLYLGLYCINE
Common Name English
3.ALPHA.,7.BETA.-DIHYDROXY-5.BETA.-CHOLANOYLGLYCINE
Systematic Name English
N-((3.ALPHA.,5.BETA.,7.BETA.)-3,7-DIHYDROXY-24-OXOCHOLAN-24-YL)GLYCINE
Systematic Name English
GLYCOURSODEOXYCHOLIC ACID
Common Name English
N-(3.ALPHA.,7.BETA.-DIHYDROXY-5.BETA.-CHOLAN-24-OYL)GLYCINE
Systematic Name English
GLYCINE, N-((3.ALPHA.,5.BETA.,7.BETA.)-3,7-DIHYDROXY-24-OXOCHOLAN-24-YL)-
Systematic Name English
GLYCYLURSODEOXYCHOLIC ACID
Common Name English
URSODEOXYCHOLYLGLYCINE, (+)-
Common Name English
Code System Code Type Description
PUBCHEM
12310288
Created by admin on Tue Mar 06 16:01:05 UTC 2018 , Edited by admin on Tue Mar 06 16:01:05 UTC 2018
PRIMARY SWITZERF
CAS
64480-66-6
Created by admin on Tue Mar 06 16:01:05 UTC 2018 , Edited by admin on Tue Mar 06 16:01:05 UTC 2018
PRIMARY
Related Record Type Details
METABOLITE -> PARENT
Unit: percent of total bile acids; Daily dose of UDCA: 1g (n=3); Duration: 2 weeks
IN-VIVO
FECAL
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
METABOLITE -> PARENT
LCA-sulfate in serum of gallstone patients given UDCA (n=7; 750mg/day [250mg in the morning, 500mg in the evening] for 2 to 3 weeks); Control (n=5): 0.1 micromole/L
IN-VIVO
PLASMA
METABOLITE ACTIVE -> PARENT
IN-VIVO
URINE
METABOLITE -> PARENT
Unit: micromole/24hr (baseline: 0.12 mcmol/24hr); Excretion of LCA-sulfate on day 10 of daily oral administration of 750mg UDCA to healthy volunteers
IN-VIVO
URINE
METABOLITE -> PARENT
Unit: micromole/g creatinine; LCA-sulfate in urine of gallstone patients given UDCA (n=6; 750mg/day [250mg in the morning, 500mg in the evening] for 2 to 3 weeks); Control (n=6): 0.4 micromole/g creatinine
IN-VIVO
URINE
METABOLITE -> PARENT
IN-VIVO
FECAL
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
METABOLITE -> PARENT
IN-VIVO
URINE
METABOLITE TOXIC -> PARENT
IN-VIVO
FECAL
PARENT -> METABOLITE
METABOLITE -> PARENT
Unit: percent of total bile acids; Daily dose of UDCA: 15mg/kg (n=6); Duration: 15 days; before treatment (7-KLCA in feces): 1 % of total bile acids
IN-VIVO
FECAL